RHB-104 is a proprietary, oral, investigational drug, antibiotic combination therapy with intracellular, antimycobacterial and anti-inflammatory properties.

RHB-104's development is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori.

RHB-104 is being developed for multiple indications, including:

RHB 104